Request Processed
Your registration request has been processed. We will contact you soon.
Register
First name
Last name
Email
Company
Toggle navigation
Toggle navigation
Login
Register
About
Contact Us
1
2
3
4
5
6
Next ›
Last »
Long-Term Opioid Study: FDA AdCom Says Proposed PMR Design Is Feasible, But Unlikely To Provide Significant Info; Is There A Safe Next Step?
April 24, 2023
MedPAC Eyeing PBMs As Next Frontier In Part D Oversight; Finance Committee “Framework” Focuses On “De-Linking” PBM Payment From Drug Prices
April 21, 2023
Prevision Policy Clips | Novavax COVID Vaccine Update Process: “Technical Challenges” Will Be Focus Of FDA Workshop April 27
April 21, 2023
Prevision Policy Clips | Cell/Gene Therapy Clinical Holds: FDA Commissioner Califf Acknowledges “Issues”
April 20, 2023
COVID Vaccine “Simplification”: Original Formula No Longer Authorized; June AdCom Will Select Strain Likely To Launch Commercially – Will Single Booster Boost Uptake?
April 19, 2023
Innoviva/Entasis SUL-DUR AdCom Goes Smoothly; FDA Office Of Infectious Diseases Shows Finesse In Moving “Streamlined” Reviews Forward
April 19, 2023
Prevision Policy Clips | FDA External Affairs Interim Head Will Be Heidi Rebello
April 19, 2023
Prevision Policy Clips | FDA Moves To Bivalent-Only COVID Vaccine Model, Authorizes Second Bivalent Booster In Some Populations
April 18, 2023
Long Wait For Long-Term Opioid Trial: FDA Seeks Committee Support For Novel Withdrawal Design To Fulfill Decade-Old Post-Marking Requirement
April 17, 2023
Otsuka/Lundbeck’s Rexulti Clears FDA Committee For Alzheimer’s Agitation: Efficacy Is Small But Clear; Mortality Risk Is “Consistent” With Class Effect
April 17, 2023
Prevision Policy Clips | COVID Vaccine “Anticipated Regulatory Changes” Prompt ACIP Meeting On Short Notice
April 17, 2023
FDA Tries Again On Opioid Relabeling: Updated Indication, New Warning About Hyperalgesia Ordered Ahead of April 19 Advisory Committee Discussion Of Delayed Post-Marketing OIH Trial
April 14, 2023
Innoviva/Entasis SUL-DUR Advisory Committee Appears Set To Showcase “Streamlined” FDA Approach To Anti-Infective Development For Unmet Needs
April 14, 2023
Prevision Policy Clips | FDA Rare Disease Endpoint Advancement (RDEA) Pilot: June 7-8 Workshop
April 14, 2023
New Technology Add-On Payments: CMS Proposes Earlier Deadline For FDA Approval To Qualify In Future Years; 19 Drugs Under Consideration For NTAP Status In FY 2024
April 13, 2023
Part B Drug Pricing Reforms Endorsed By MedPAC: Is There Appetite For More Changes Amid IRA Implementation?
April 13, 2023
Prevision Policy Clips | Pragmatica-Lung Phase 3 Advanced NSCLC Survival Trial With Cyramza/Keytruda
April 13, 2023
FDA Guidance “Snapshots” Pilot Explained: CDER Describes Purpose Of Initiative, Patient-Directed Explanations Up Next
April 12, 2023
Otsuka/Lundbeck’s Rexulti In Alzheimer’s Agitation Benefit/Risk To Be Debated By FDA Advisory Committee: Can An Appropriate Population Be Identified?
April 12, 2023
Shortage Notification Guidance Updated: COVID-Era Message To Manufacturers To Err On The Side Of Informing FDA Will Continue Post-Pandemic
April 12, 2023
Prevision Policy Clips | Quantity Reporting: FDA Finalizes Exemption For Single-Use Gene/Cell Therapy Lots
April 12, 2023
Prevision Policy Clips | CMS Projects Novel Anti-Infectives Could Net $213 Mil. In Add-On Payments For FY 2024
April 11, 2023
Prevision Policy Clips | Sarepta DMD Gene Therapy Advisory Committee Set For May 12
April 10, 2023
Prevision Policy Clips | Makena And Generics Formally Withdrawn Immediately, FDA Commissioner Califf And Chief Scientist Bumpus
April 7, 2023
Accelerated Approval Planning For Rare Diseases: FDA “ARC” Initiative Aims To Encourage Early Discussions – Even At Pre-IND Phase
April 7, 2023
1
2
3
4
5
6
Next ›
Last »